Literature DB >> 17047111

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

I N Guha1, J Parkes, P R Roderick, S Harris, W M Rosenberg.   

Abstract

The diagnosis of fibrosis within liver disease is important for prognosis, stratification for treatment, and monitoring of treatment efficacy. The rising incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) has driven the search for accurate non-invasive tools of liver fibrosis within this condition. With the aid of a systematic review, we explore how the field has evolved from the discovery of simple blood parameters to panel markers of liver fibrosis. We will discuss the biological plausibility, limitations, potential uses, and emerging diagnostic techniques of non-invasive markers in this rapidly expanding field.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047111      PMCID: PMC1860097          DOI: 10.1136/gut.2006.091454

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  52 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease.

Authors:  Zobair M Younossi; Ancha Baranova; Katharine Ziegler; Luca Del Giacco; Karen Schlauch; Timothy L Born; Hazem Elariny; Francesco Gorreta; Amy VanMeter; Abraham Younoszai; Janus P Ong; Zachary Goodman; Vikas Chandhoke
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

3.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

4.  The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease.

Authors:  Etsuko Hashimoto; Saturu Yatsuji; Hiroyuki Kaneda; Yoko Yoshioka; Makiko Taniai; Katsutoshi Tokushige; Keiko Shiratori
Journal:  Hepatol Res       Date:  2005-10-03       Impact factor: 4.288

5.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

6.  Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis.

Authors:  E Albano; E Mottaran; M Vidali; E Reale; S Saksena; G Occhino; A D Burt; C P Day
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.

Authors:  J Foucher; E Chanteloup; J Vergniol; L Castéra; B Le Bail; X Adhoute; J Bertet; P Couzigou; V de Lédinghen
Journal:  Gut       Date:  2005-07-14       Impact factor: 23.059

9.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

10.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

View more
  32 in total

1.  Fatty liver disease in children: eat now pay later.

Authors:  Ruth M L De Bruyne; Emer Fitzpatrick; Anil Dhawan
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

Review 2.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Elevation of alanine transaminase and markers of liver fibrosis after a mixed meal challenge in individuals with type 2 diabetes.

Authors:  E Y H Khoo; M C Stevenson; E Leverton; R Cross; J W Eriksson; S M Poucher; I Spendlove; P G Morris; I A Macdonald; P Mansell; G P Aithal
Journal:  Dig Dis Sci       Date:  2012-05-17       Impact factor: 3.199

4.  Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis.

Authors:  Mireen Friedrich-Rust; Hassan Hadji-Hosseini; Susanne Kriener; Eva Herrmann; Ishani Sircar; Annika Kau; Stefan Zeuzem; Joerg Bojunga
Journal:  Eur Radiol       Date:  2010-06-06       Impact factor: 5.315

5.  Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Authors:  Hye Ran Yang; Hae Ryoung Kim; Myung Jin Kim; Jae Sung Ko; Jeong Kee Seo
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

6.  The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Authors:  Sana Mansoor; Lisa Yerian; Rohit Kohli; Stavra Xanthakos; Paul Angulo; Simon Ling; Rocio Lopez; Carter-Kent Christine; Ariel E Feldstein; Naim Alkhouri
Journal:  Dig Dis Sci       Date:  2014-12-25       Impact factor: 3.199

7.  Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified?

Authors:  Antonio Ramos-De la Medina; José M Remes-Troche; Federico B Roesch-Dietlen; Alfonso G Pérez-Morales; Silvia Martinez; Silvia Cid-Juarez
Journal:  J Gastrointest Surg       Date:  2008-09-30       Impact factor: 3.452

8.  Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).

Authors:  Joanna Raszeja-Wyszomirska; Barbara Szymanik; Małgorzata Ławniczak; Maciej Kajor; Alina Chwist; Piotr Milkiewicz; Marek Hartleb
Journal:  BMC Gastroenterol       Date:  2010-06-28       Impact factor: 3.067

9.  Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis.

Authors:  Tarek E Korah; Sawsan El-Sayed; Maathir K Elshafie; Ghada E Hammoda; Manal A Safan
Journal:  World J Hepatol       Date:  2013-02-27

10.  Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.

Authors:  Marlyn J Mayo; Julie Parkes; Beverley Adams-Huet; Burton Combes; A S Mills; Rodney S Markin; Raphael Rubin; Donald Wheeler; Melissa Contos; A B West; Sandra Saldana; Yonas Getachew; Robert Butsch; Velimir Luketic; Marion Peters; Adrian Di Bisceglie; Nathan Bass; John Lake; Thomas Boyer; Enrique Martinez; James Boyer; Guadalupe Garcia-Tsao; David Barnes; William M Rosenberg
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.